Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06582017 · ClinicalTrials.gov registry record · Phase 1
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Nammi Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 8
- Study locations
NCT06582017: Recruiting Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by Nammi Therapeutics.
NCT06582017 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by Nammi Therapeutics. The registered enrollment target is 100 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06582017, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by Nammi Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 8
- Study locations
Study Summary
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical starting dose. Dose escalation in solid tumors (Part A1) will be followed by dose finding in multiple myeloma (Part A2). Part B consists of dose expansion in solid tumors (Part B1) and multiple myeloma (Part B2) using the recommended dose for expansion from Part A
Primary Outcome
Record all safety events during study including AEs, SAEs, DLTs, AESIs.
Conditions Studied
Interventions
- BIOLOGICAL QXL138AM Injection every 2 weeks by IV Infusion
Study Locations (8)
California
- University of Southern California - Los Angeles
- Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport
New York
- New York Cancer & Blood Specialists - New York
- University of Rochester - Wilmot Cancer Institute - Rochester
Colorado
- Sarah Cannon Research Institute - Denver DDU - Denver
Georgia
- Emory University - Winship Cancer Institute - Atlanta
Texas
- START San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-08-28 |
| Est. Completion | 2028-05-30 |
| Phase | Phase 1 |
What NCT06582017 shows while recruiting
NCT06582017 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which QXL138AM Injection every 2 weeks by IV Infusion is the first listed.
NCT06582017 lists 8 locations in 5 states (California, New York, Colorado).
Frequently Asked Questions
What is clinical trial NCT06582017 about?
NCT06582017 is a clinical study titled "Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma". Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduct...
What is the current status of trial NCT06582017?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-08-28. Estimated completion is 2028-05-30.
What conditions does trial NCT06582017 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer, Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06582017?
The interventions under investigation include: QXL138AM Injection every 2 weeks by IV Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT06582017?
This trial is sponsored by Nammi Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06582017 being conducted?
This trial has 8 study locations across California, Colorado, Georgia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06582017's enrollment target sits among peer trials
100 565th of 1224 higher than 630 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI